Status:
RECRUITING
Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations
Lead Sponsor:
Qilu Hospital of Shandong University
Collaborating Sponsors:
First Affiliated Hospital, Sun Yat-Sen University
First Affiliated Hospital of Guangxi Medical University
Conditions:
Pancreatic Ductal Adenocarcinoma
Pancreatic Diseases
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective cohort study. The investigators enroll subjects with pancreatic ductal adenocarcinoma (PDAC), individuals at high risk for PDAC, patients with other pancreatic diseases, patients...
Eligibility Criteria
Inclusion
- Case groups (matching any of the following):
- Patients with pancreatic cancer with recognized diagnostic criteria or conclusions.
- Patients who are the high-risk group of pancreatic cancer.
- Patients with solid pseudo papilloma and neuroendocrine tumors of pancreas with recognized diagnostic criteria or conclusions.
- Patients with other diseases with abnormally elevated CA19-9.
- Control group:
- (1) Patients without pancreatic disease assessed by laboratory tests and imaging examinations have no CA19-9 elevation.
Exclusion
- Patients who are younger than 18 years of age.
- Patients with suspected pancreatic malignant lesions but has no confirmed imaging or pathological diagnosis.
- Patients who have not signed informed consent.
Key Trial Info
Start Date :
May 5 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
2100 Patients enrolled
Trial Details
Trial ID
NCT06041009
Start Date
May 5 2023
End Date
September 30 2025
Last Update
October 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ning Zhong
Jinan, Shandong, China, 250063